Skip to main content
. 2017 Aug 7;8(41):70828–70840. doi: 10.18632/oncotarget.19993

Figure 5. TDP-A treatment alters NE phenotypic markers.

Figure 5

Two-day TDP-A treatment results in a dose-dependent reduction of NE tumor markers achaete-scute complex like 1 (ASCL1), chromogranin A (CgA) and synaptophysin (SYN) in all three NE cancer cell lines. GAPDH was used as loading control.